4-chloro-5,7,8,9-tetrahydrothiopyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-chloro-5,7,8,9-tetrahydrothiopyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidine
• 英文别名: 4-chloro-5,7,8,9-tetrahydrothiopyrano[3’,4’:4,5]pyrrolo[2,3-d]pyrimidine；3-Chloro-12-thia-4,6,8-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5-tetraene；3-chloro-12-thia-4,6,8-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5-tetraene
• 化学式: C₉H₈ClN₃S
• 分子量: 225.702
• InChiKey: AUJSUNAPFKCJEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-5,7,8,9-tetrahydrothiopyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidine 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以49%的产率得到4-chloro-5,7,8,9-tetrahydrothiopyrano[3',4':4,5]pyrrolo[2,3-d]pyrimidine 6,6-dioxide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRROLOPYRIMIDINES
  [FR] PYRROLOPYRIMIDINES SUBSTITUÉES

  摘要：

  本发明涉及一般式I的取代吡咯吡嘧啶化合物，其中A、X、R1、R2、m和n如本文所述和定义，以制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防高增殖和/或血管生成障碍的疾病，作为唯一药剂或与其他活性成分组合使用。

  公开号：

  WO2013174743A1

文献信息

• 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3915990A1

  公开（公告）日：2021-12-01

  The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

  本发明涉及一种化合物，特别是作为LIMK和/或ROCK激酶抑制剂的化合物（I）的公式。本发明还涉及这些新抑制剂的用途，用于治疗所选组中的疾病，包括：癌症、病毒感染、眼压增高和青光眼形成、神经纤维瘤病1和2型、银屑病损、炎症性疾病和过敏症、中枢敏化和慢性疼痛、生殖勃起功能障碍和神经疾病。本说明披露了示例化合物的合成和表征，以及其药理学数据（例如第32至127页；示例1至96；家族1至8；化合物；生物学研究；表格）。一个示例化合物是4-(5-甲基-7H-吡咯并[2,3-d]嘧啶-4-基)-N-苯基-3,6-二氢吡啶-1-(2H)-甲酰胺（示例1；化合物5）。
• SUBSTITUTED PYRROLOPYRIMIDINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150133426A1

  公开（公告）日：2015-05-14

  The present invention relates to substituted pyrrolopyrimidine compounds general formula I: in which A, X, R 1 , R 2 , m and n are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及替代吡咯吡嘧啶化合物通式I：其中A、X、R1、R2、m和n如本文所述和定义的那样，以及制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的制药组合物和组合物，以及用于制造治疗或预防疾病的制药组合物的使用，特别是治疗或预防增殖过度和/或血管生成障碍的疾病，作为唯一的治疗剂或与其他活性成分组合使用。
• [EN] 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE SERVANT D'INHIBITEURS DE KINASES LIMK ET/OU ROCK DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2021239727A1

  公开（公告）日：2021-12-02

  The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 37 to 163; examples 1 to 169; compounds; biological studies; tables; figure pages 1/6 to 6/6). An exemplary compound is e.g. 4-(5-methyl-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).
• [EN] SUBSTITUTED PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2013174743A1

  公开（公告）日：2013-11-28

  The present invention relates to substituted pyrrolopyrimidine compounds general formula I : in which A, X, R1, R2, m and n are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式I的取代吡咯吡嘧啶化合物，其中A、X、R1、R2、m和n如本文所述和定义，以制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防高增殖和/或血管生成障碍的疾病，作为唯一药剂或与其他活性成分组合使用。